In tumor treatment, people are not surprised to see such a drastic treatment as surgery plus radiotherapy. However, the article published in the New England Journal of Medicine today by our scholars Hongwan and Xiaojun Huang is particularly noteworthy, as their study confirms that patients with acute early-stage granulocytic leukemia can achieve good results with only two drugs taken orally for eight months. This concept of “subtraction” in tumor treatment is also the wish of many doctors and patients. The incidence of acute promyelocytic leukemia is not very high, usually accounting for about 10% of adult acute leukemia, but because patients are mainly young adults, it is important to improve the cure rate and quality of life for these patients. In the early stages of clinical treatment, patients require prolonged hospitalization, and the toxic side effects of chemotherapy drugs force many patients to interrupt their education or work to focus on treatment. In order to simplify patient treatment, based on previous studies, we proposed the bold idea of changing the traditional chemotherapy, vincristine and intravenous arsenic regimen to oral arsenic administration. after studying 242 patients between 2007 and 2012, we finally confirmed that in the treatment of patients with acute promyelocytic leukemia, arsenic In 2013, the study was published in the top international journal of Clinical Oncology. Coincidentally, Italian scholars also conducted a study on acute promyelocytic leukemia from 2007 to 2012, in which they confirmed that retinoic acid combined with intravenous arsenic therapy was superior to retinoic acid combined with chemotherapy in 156 patients, and confirmed for the first time in the world through a randomized controlled study that chemotherapy could be dispensed with just two drugs, retinoic acid and intravenous arsenic. The article was published in the New England Journal of Medicine in 2013, and the absence of chemotherapy drugs not only allows patients to stay away from the toxic side effects of chemotherapy, but also gives us hope for further simplification of treatment. In February 2013, we quickly designed a new study protocol and this year confirmed the feasibility of the ideal model of “no chemotherapy, no infusion, and only two oral drugs for acute promyelocytic leukemia”. The combination of retinoic acid and arsenic as the preferred treatment for acute promyelocytic leukemia has been called a “dream combination” with a cure rate of over 90%. In our study, we enrolled 20 non-high-risk acute promyelocytic leukemia patients (white blood cells less than 10,000) who were treated with only two oral drugs (Fuze Huang Dai tablets and retinoic acid), no traditional chemotherapy drugs, no infusion, no hospitalization after remission, and a total treatment duration of 8 months. The results showed that all patients achieved complete remission, and with the help of the most sensitive quantitative PCR test available for leukemia-specific fusion genes, it was confirmed that all patients in the study achieved a negative leukemia gene conversion, suggesting that these patients have a high chance of complete cure in the future. The study was published in the December 4, 2014 issue of the New England Journal of Medicine, one of the top journals in the field of medicine [Hong-Hu Zhu, Xiao-Jun Huang, NEJM, 2014; 371:2239-2241], with an impact factor of 54.42. The team has published two consecutive research articles in the series in the New England Journal of Medicine this year, which is of historical importance. For patients, this concise treatment option allows them to have a near-normal quality of life during treatment without interfering with normal work and school, while the cost of medical care is significantly reduced. For us physicians, this may bring new insights – we may be able to do simpler in oncology treatment.